Beta-blockers after Acute Coronary Syndrome: Does atrial fibrillation change the equation? A Portuguese multicentre national registry analysis
Introduction: Beta-blockers (BB) remain a cornerstone of secondary prevention after acute coronary syndrome (ACS). However, contemporary randomized trials have questioned their routine use in patients with preserved ejection fraction, often excluding those with atrial fibrillation (AF). We aimed to evaluate the prognost...